InMed Pharmaceuticals (DE:MWG)
FRANKFURT:MWG
MWG Stock Chart & Stats
€0.85
-€0.14(-2.97%)
At close: 4:00 PM EST
€0.85
-€0.14(-2.97%)
Day’s Range― - ―
52-Week Range€0.47 - €6.60
Previous CloseN/A
Volume0.00
Average Volume (3M)50.00
Market Cap
€1.62M
Enterprise Value-€7.65M
Total Cash (Recent Filing)€9.60M
Total Debt (Recent Filing)€730.14K
Price to Earnings (P/E)―
Beta2.67
Next Earnings
May 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.44
Shares Outstanding2,919,186
10 Day Avg. Volume150
30 Day Avg. Volume50
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.17
Price to Sales (P/S)0.64
P/FCF Ratio-0.41
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Balance-sheet StrengthVery low debt-to-equity across reported periods gives InMed structural financial flexibility. Limited leverage reduces bankruptcy and refinancing risk, enabling the company to prioritize R&D and regulatory milestones without heavy interest burdens, a durable advantage for a clinical-stage biotech.
Revenue Growth And Improving Gross MarginMulti-year revenue growth and a notable gross margin improvement indicate underlying commercial or manufacturing progress. Sustained top-line momentum and better product economics can support longer-term R&D funding and improve scalability if clinical programs validate the technology.
Advancing Pipeline And Regulatory RoadmapConsistent preclinical results plus explicit pre-IND and IND-enabling timelines represent a structural shift from commodity ingredients toward proprietary therapeutics. Progress toward first-in-human studies can materially de-risk programs and create durable value drivers via licensing or approvals.
Bears Say
Persistent Cash Burn And Weak Cash GenerationRepeated negative operating cash flow and sizable free-cash-flow deficits create structural funding pressure for a clinical-stage biotech. Limited cash on hand and high burn require ongoing external financing, risking dilution and constraining long-term program execution if capital markets tighten.
Large Operating And Net Losses; Far From BreakevenExtremely negative operating and net margins show the core business is not near profitability. Persistent losses depress returns on equity and require continual financing, which impairs long-term shareholder value creation until clinical or commercial inflection points are achieved.
Nasdaq Minimum Bid Noncompliance & Listing RiskA formal Nasdaq deficiency creates structural governance and execution risk: management may need to pursue reverse splits or other corporate actions, which can dilute liquidity, complicate capital raises, and distract management from R&D priorities over the medium term.
InMed Pharmaceuticals News
MWG FAQ
What was InMed Pharmaceuticals’s price range in the past 12 months?
InMed Pharmaceuticals lowest stock price was €0.47 and its highest was €6.60 in the past 12 months.
What is InMed Pharmaceuticals’s market cap?
InMed Pharmaceuticals’s market cap is €1.62M.
When is InMed Pharmaceuticals’s upcoming earnings report date?
InMed Pharmaceuticals’s upcoming earnings report date is May 18, 2026 which is in 38 days.
How were InMed Pharmaceuticals’s earnings last quarter?
InMed Pharmaceuticals released its earnings results on Feb 11, 2026. The company reported -€0.44 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.44.
Is InMed Pharmaceuticals overvalued?
According to Wall Street analysts InMed Pharmaceuticals’s price is currently Overvalued.
Does InMed Pharmaceuticals pay dividends?
InMed Pharmaceuticals does not currently pay dividends.
What is InMed Pharmaceuticals’s EPS estimate?
InMed Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does InMed Pharmaceuticals have?
InMed Pharmaceuticals has 2,919,186 shares outstanding.
What happened to InMed Pharmaceuticals’s price movement after its last earnings report?
InMed Pharmaceuticals reported an EPS of -€0.44 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -14.013%.
Which hedge fund is a major shareholder of InMed Pharmaceuticals?
Currently, no hedge funds are holding shares in DE:MWG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
InMed Pharmaceuticals
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
Technical Analysis
Alaunos Therapeutics
―
―
Xenetic Biosciences
―
Ensysce Biosciences
―
Pasithea Therapeutics Corp
―
Options Prices
Currently, No data available
---